About: Ultrasensitive Monitoring of HIV-1 Viral Load by a Low-Cost Real-Time Reverse Transcription-PCR Assay with Internal Control for the 5′ Long Terminal Repeat Domain

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ultrasensitive Monitoring of HIV-1 Viral Load by a Low-Cost Real-Time Reverse Transcription-PCR Assay with Internal Control for the 5′ Long Terminal Repeat Domain Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Ultrasensitive Monitoring of HIV-1 Viral Load by a Low-Cost Real-Time Reverse Transcription-PCR Assay with Internal Control for the 5′ Long Terminal Repeat Domain
Creator	Drosten, Christian Preiser, Wolfgang Panning, Marcus Doerr, Hans Drexler, Jan Kleber, Luciano Luna, Souza Brites, Carlos Liedigk, Britta Lippert, Ute Pedroso, Celia Samuel, Matthew Yeats, Jane Hä, Florian Stü, Martin
Source	PMC
abstract	Background: Current HIV-1 viral-load assays are too expensive for resource-limited settings. In some countries, monitoring of antiretroviral therapy is now more expensive than treatment itself. In addition, some commercial assays have shown shortcomings in quantifying rare genotypes. Methods: We evaluated real-time reverse transcription-PCR with internal control targeting the conserved long terminal repeat (LTR) domain of HIV-1 on reference panels and patient samples from Brazil (n = 1186), South Africa (n = 130), India (n = 44), and Germany (n = 127). Results: The detection limit was 31.9 IU of HIV-1 RNA/mL of plasma (>95% probability of detection, Probit analysis). The internal control showed inhibition in 3.7% of samples (95% confidence interval, 2.32%–5.9%; n = 454; 40 different runs). Comparative qualitative testing yielded the following: Roche Amplicor vs LTR assay (n = 431 samples), 51.7% vs 65% positives; Amplicor Ultrasensitive vs LTR (n = 133), 81.2% vs 82.7%; BioMerieux NucliSens HIV-1 QT (n = 453), 60.5% vs 65.1%; Bayer Versant 3.0 (n = 433), 57.7% vs 55.4%; total (n = 1450), 59.0% vs 63.8% positives. Intra-/interassay variability at medium and near-negative concentrations was 18%–51%. The quantification range was 50–10 000 000 IU/mL. Viral loads for subtypes A–D, F–J, AE, and AG yielded mean differences of 0.31 log(10) compared with Amplicor in the 10(3)–10(4) IU/mL range. HIV-1 N and O were not detected by Amplicor, but yielded up to 180 180.00 IU/mL in the LTR assay. Viral loads in stored samples from all countries, compared with Amplicor, NucliSens, or Versant, yielded regression line slopes (SD) of 0.9 (0.13) (P <0.001 for all). Conclusions: This method offers all features of commercial assays and covers all relevant genotypes. It could allow general monitoring of antiretroviral therapy in resource-limited settings.
has issue date	2006-07-01(xsd:dateTime)
bibo:doi	10.1373/clinchem.2006.066498
bibo:pmid	16627558
has license	no-cc
sha1sum (hex)	d28a2b8b103901fbcac1df3c927554eae63c32f8
schema:url	https://doi.org/10.1373/clinchem.2006.066498
resource representing a document's title	Ultrasensitive Monitoring of HIV-1 Viral Load by a Low-Cost Real-Time Reverse Transcription-PCR Assay with Internal Control for the 5′ Long Terminal Repeat Domain
has PubMed Central identifier	PMC7108179
has PubMed identifier	16627558
schema:publication	Clin Chem
resource representing a document's body	covid:d28a2b8b103901fbcac1df3c927554eae63c32f8#body_text
is schema:about of	named entity 'Brazil' named entity 'LTR' named entity 'Long' named entity 'RUNS' named entity 'SOUTH AFRICA' named entity 'HIV-1 RNA' named entity 'HAVE' named entity 'REFERENCE' named entity 'GERMANY' named entity 'MONITORING' named entity 'Roche' named entity 'genotypes' named entity 'Methods' named entity 'antiretroviral therapy' named entity 'evaluated' named entity 'LTR' named entity 'confidence interval' named entity 'assay' named entity 'internal control' named entity 'detection limit' named entity 'South Africa' named entity 'assay' named entity 'internal control' named entity 'LTR' named entity 'probability of detection' named entity 'India' named entity '95% confidence interval' named entity 'Long Terminal Repeat' named entity 'Internal Control' named entity 'Viral Load' named entity 'Reverse Transcription' named entity 'real-time PCR' named entity 'Promega' named entity 'nucleic acid' named entity 'HIV-1' named entity 'Promega' named entity 'open format' named entity 'internal control' named entity 'HIV-1' named entity 'University of Frankfurt' named entity 'PCR' named entity 'Brazil' named entity 'plasma' named entity 'transcription' named entity 'WHO' named entity 'AVL' named entity 'WHO' named entity 'regression analyses' named entity 'plasma' named entity 'nucleotide' named entity 'RNA' named entity 'hiv-1' named entity 'molecular methods' named entity 'milk' named entity 'Invitrogen' named entity 'BioMerieux' named entity 'Germany' named entity 'virus' named entity 'fresh-frozen plasma' named entity 'rhodamine' named entity 'LTR' named entity 'Northern Hemisphere' named entity 'LTR' named entity 'Clinical Chemistry' named entity 'nuclease' named entity 'plasma' named entity 'pCR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software